{
    "name": "ferric gluconate",
    "comment": "Rx",
    "other_names": [
        "Ferrlecit"
    ],
    "classes": [
        "Iron Products"
    ],
    "source": "https://reference.medscape.com/drug/ferrlecit-ferric-gluconate-342159",
    "pregnancy": {
        "common": [
            "Parenteral iron administration may be associated with hypersensitivity reactions, which may have serious consequences, such as fetal bradycardia",
            "Advise pregnant women of potential risk to fetus; available data from postmarketing reports with Ferrlecit use in pregnancy are insufficient to assess risk of major birth defects and miscarriage",
            "Ferrlecit contains benzyl alcohol as a preservative; because benzyl alcohol is rapidly metabolized by a pregnant woman, benzyl alcohol exposure in fetus is unlikely. However, adverse reactions have occurred in premature neonates and low birth weight infants who received intravenously administered benzyl alcohol-containing drugs",
            "Consider alternative iron replacement therapies without benzyl alcohol",
            "There are risks to mother and fetus associated with untreated iron deficiency anemia in pregnancy ",
            "In absence of maternal toxicity, Ferrlecit was not teratogenic to offspring of pregnant mice or rats at clinically relevant exposures",
            "Untreated iron deficiency anemia (IDA) in pregnancy is associated with adverse maternal outcomes such as postpartum anemia; adverse pregnancy outcomes associated with IDA include increased risk for preterm delivery and low birth weight",
            "Severe adverse reactions including circulatory failure (severe hypotension, shock including in the context of anaphylactic reaction) may occur in pregnant women with intravenous iron administration which may have serious consequences on fetus such as fetal bradycardia, especially during second and third trimester"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Drug contains benzyl alcohol; because benzyl alcohol is rapidly metabolized by a lactating woman, benzyl alcohol exposure in breastfed infant is unlikely; however, adverse reactions have occurred in premature neonates and low birth weight infants who received intravenously administered benzyl alcohol-containing drugs; consider alternative iron replacement therapies without benzyl alcohol for use during lactation",
            "There are no available data on presence of Ferrlecit in human or animal milk, effects on milk production, or on breastfed child"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to drug or excipients"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "DO NOT mix Ferrlecit with other meds or add to TPN; compatibility has not been established",
                "Excessive therapy with parenteral iron can lead to excess storage of iron with possibility of iatrogenic hemosiderosis; patients receiving therapy require periodic monitoring of hematologic and iron parameters (hemoglobin, hematocrit, serum ferritin, and transferrin saturation)"
            ],
            "specific": [
                {
                    "type": "Adverse effects due to benzyl alcohol",
                    "description": [
                        "Not approved for use in neonates or infants; serious and fatal adverse reactions including “gasping syndrome” can occur in neonates and low-birth-weight infants treated with benzyl alcohol–preserved drugs",
                        "The “gasping syndrome” is characterized by central nervous system depression, metabolic acidosis, and gasping respirations; minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known"
                    ]
                },
                {
                    "type": "Hypersensitivity",
                    "description": [
                        "Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, reported in patients receiving drug in postmarketing experience",
                        "Patients may present with shock, clinically significant hypotension, loss of consciousness, or collapse",
                        "Monitor patients for signs and symptoms of hypersensitivity during and after administration for at least 30 minutes and until clinically stable following completion of the infusion",
                        "Only administer drug when personnel and therapies are immediately available for treatment of anaphylaxis and other hypersensitivity reactions"
                    ]
                },
                {
                    "type": "Hypotension",
                    "description": [
                        "Therapy may cause clinically significant hypotension",
                        "Hypotension associated with lightheadedness, malaise, fatigue, weakness or severe pain in the chest, back, flanks, or groin reported",
                        "Hypotensive reactions may or may not be associated with signs and symptoms of hypersensitivity reactions and usually resolve within one to two hours",
                        "Transient hypotension may occur during dialysis; administration may augment hypotension caused by dialysis; monitor patients for signs and symptoms of hypotension during and following administration"
                    ]
                },
                {
                    "type": "Drug interactions overview",
                    "description": [
                        "Drug-drug interactions not studied; drug may reduce absorption of concomitantly administered oral iron preparations"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Diarrhea",
            "percent": "35"
        },
        {
            "name": "Nausea",
            "percent": "35"
        },
        {
            "name": "Vomiting",
            "percent": "35"
        },
        {
            "name": "Injection site reaction",
            "percent": "33"
        },
        {
            "name": "Hypotension",
            "percent": "29"
        },
        {
            "name": "Cramps",
            "percent": "25"
        },
        {
            "name": "Dizziness",
            "percent": "13"
        },
        {
            "name": "Hypertension",
            "percent": "13"
        },
        {
            "name": "Dyspnea",
            "percent": "11"
        },
        {
            "name": "Chest pain",
            "percent": "10"
        },
        {
            "name": "Asthenia",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Syncope",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Fever",
            "percent": null
        },
        {
            "name": "Edema",
            "percent": null
        },
        {
            "name": "Cough",
            "percent": null
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "Hyperkalemia",
            "percent": null
        },
        {
            "name": "Electrolyte abnormalities",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Leg cramps",
            "percent": null
        },
        {
            "name": "Cardiovascular System",
            "percent": null
        },
        {
            "name": "Shock",
            "percent": null
        },
        {
            "name": "fetal bradycardia",
            "percent": null
        },
        {
            "name": "injection site superficial thrombophlebitis",
            "percent": null
        },
        {
            "name": "phlebitis",
            "percent": null
        },
        {
            "name": "acute myocardial ischemia with or without myocardial infarction with in",
            "percent": null
        },
        {
            "name": "stent thrombosis in the context of hypersensitivity reaction",
            "percent": null
        },
        {
            "name": "Gastrointestinal System",
            "percent": null
        },
        {
            "name": "Dysgeusia",
            "percent": null
        },
        {
            "name": "Immune System",
            "percent": null
        },
        {
            "name": "Anaphylactic",
            "percent": null
        },
        {
            "name": "type reactions",
            "percent": null
        },
        {
            "name": "Nervous System",
            "percent": null
        },
        {
            "name": "Loss of consciousness",
            "percent": null
        },
        {
            "name": "generalized convulsion",
            "percent": null
        },
        {
            "name": "hypoesthesia",
            "percent": null
        },
        {
            "name": "Skin and Appendages",
            "percent": null
        },
        {
            "name": "skin discoloration",
            "percent": null
        },
        {
            "name": "pallor",
            "percent": null
        }
    ]
}